CN104127432A - Pharmaceutical composition for treating amentia - Google Patents
Pharmaceutical composition for treating amentia Download PDFInfo
- Publication number
- CN104127432A CN104127432A CN201410391892.2A CN201410391892A CN104127432A CN 104127432 A CN104127432 A CN 104127432A CN 201410391892 A CN201410391892 A CN 201410391892A CN 104127432 A CN104127432 A CN 104127432A
- Authority
- CN
- China
- Prior art keywords
- amentia
- pharmaceutical composition
- parts
- arginine
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicines and specifically relates to a pharmaceutical composition for treating amentia. The pharmaceutical composition is prepared from the following materials in parts by weight: 5.6 parts of L-methyl calcium foliate, 2 parts of methyl vitamin B12, 600 parts of N- acetylcysteine and 200-600 parts of arginine. By addition of the arginine, the pharmaceutical composition disclosed by the invention can be applied to people with arginine deficiency, has the advantages of a wider scope of adaptation diseases, enhanced effect and capability of improving and restoring memory and cognitive abilities.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of pharmaceutical composition for the treatment of amentia.
Background technology
The loss of memory is an old and feeble performance.Some old people's metabolism and genetic imbalance can accelerate the loss of memory, and As time goes on, this mild cognitive impairment (MCI) can worsen.This class is slight brain patient suffering intellectual disturbance, just has one will develop into Alzheimer's disease in two people.
Patient's loss of memory has arrived the upset daily life order of severity, is not what just caused quickly.Perhaps start from mild cognitive impairment or be similar to Pre-Alzheimer Symptoms in early stage, further cause brain thinking, inferential capability slowly to fail, finally cause a kind of fatal cerebral disorders (senile dementia).
The undernutrition that brain needs causes brain aging.If you have the difficulty of remembeing or become more forgetful, this may be the sign of early memory decline.Brain supplements useful nutrient substance, contributes to the neuron in brain to avoid infringement, reduces the risk of suffering from Alzheimer's disease.
Summary of the invention
The object of this invention is to provide a kind of pharmaceutical composition for the treatment of amentia, safety, substantially have no side effect, expanded the suitability.
The pharmaceutical composition for the treatment of amentia of the present invention, by the raw material of following parts by weight, made:
The present invention can make pharmaceutically acceptable various preparation.
Preparation method: after raw material is mixed, be prepared into according to a conventional method loose, ball, sheet or capsule preparations.
Usage and consumption: the quality of every capsules is 810-1210mg, one of capsule every day, take night, within 30 days, is a course for the treatment of, the same capsule of other dosage form usage and dosage.
Pharmacology:
Metafolin or (6s)-5-methyltetrahydrofolate [6 (S)-5-MTHF], be the isomer with bioactive folic acid, and the existence form of folic acid in circulation.Activity form could cross-film be carried, and particularly passes through blood brain barrier.In cell, 6 (S)-5-MTHF are for homocysteine is methylated, and generate methionine and tetrahydrofolic acid (THF).Oxolane is the direct receptor of the synthetic one carbon unit of thymine DNA, for the synthesis of purine (RNA and DNA) and methionine.Folic acid must become biological activity folic acid by Methylene tetrahydrofolate reductase (MTHFR) enzymatic reduction.Some genetic mutations cause being converted into by the folic acid of naturalness active 6 (S)-5-methyltetrahydrofolates.
Methylcobalamin is two kinds and has a kind of in bioactive vitamin B12.Methyl B12 is the principal mode of circulation vitamin B12, with this form, is transported to peripheral tissues.Cyanocobalamin and hydroxocobalamine are that needs just can be converted to methylcobalamin by glutathion-vitamin B12 intermediate.Vitamin B12 is significant to safeguarding nervous system normal function, also participates in the physiological process relevant with B12.The B12 that is deficient in vitamin can cause anemia, amentia, nervous function disorder etc. disease.Old and feeble and numerous disease all can cause vitamin B 12 activity obstacle, causes cardio-cerebrovascular diseases.
N-acetylcystein (NAC) is glutathione precursor (GSH), and glutathion is the most effective a kind of Natural antioxidant in human body.In N-acetylcystein cell, be converted into glutathion.Keep suitable Intracellular Glutathione (GSH), contribute to maintain cerebrovascular tissue metabolism vitamin B12 ability, reduce or eliminate at these in-house oxidation emergencies.N-acetylcystein significantly reduces the concentration of homocysteine in plasma, and increases total antioxidant capacity (TAC), thereby corrects the cognitive dysfunction that hyperhomocysteinemiainjury causes.
Arginine is half necessary aminoacid, is synthesize the direct precursor of NO and safeguard nervous system, the necessary bioactive substance of blood circulation normal function.
" L-methylfolate{6 (s)-5-MTHF} (6s)-5-methyltetrahydrofolate calcium (Metafolin); Methylcobalamin mecobalamin, N-Acetylcysteine N-acetylcystein " said composition (cerefolin NAC) is that slight amentia medicine is treated in FDA approval clinical practice.This combination provides synthetic NO (nitric oxide) the auxiliary enzymes factor and antioxidant.Arginine is the direct precursor of the synthetic NO of endotheliocyte, there is the effect of the synthase activity of enhancing, arginine is combined use with metafolin { (6s)-5-methyltetrahydrofolate calcium } and methylcobalamin, can further promote NO to produce, thereby can make endotheliocyte synthesize more NO, recovery, improvement and blood circulation promoting, thus recover and improve intellectually challenged and remember and other brain function.
The present invention compared with prior art, more effectively increases cerebral blood flow, improves brain function, more effective treatment amentia.
Curative effect judgement:
Recovery from illness: disease all disappears.
Take a turn for the better: disease is clearly better.
Invalid: disease is not improved.
Therapeutic outcome: 2010-2014 is clinical treats observation to 185 routine patients.48 examples of fully recovering, account for 25.95%, and 85 examples that take a turn for the better, account for 45.95%, and invalid 52 examples, account for 28.1%, total effective rate 71.9%.
The amentia disease that the present invention causes disturbance of blood circulation and some metabolic dysfunction has good effect, is particularly useful for cerebrovascular property amentia, particularly has treatment, rehabilitative action.The remarkable effective percentage of old amentia rehabilitation sufferer is more than 70%.
The present invention compared with prior art, has following beneficial effect:
Safety of the present invention, has no side effect substantially, is the useful nutritional supplementation constituents of needed by human body.
Compared with prior art, the invention provides arginine (NO synthesizes precursor), therefore expand the adaptation medication that arginine lacks crowd to (such as arginine is with age decayed, particularly old amentia initial stage patient's arginine more lacks), be not only that arginine shortage crowd supplements arginine, it is combined with methopterin and methyl B12, the more effective inner skin cell function that improves, blood circulation promoting, improves amentia patient's memory and cognitive ability and other brain function.
Compared with prior art, indication of the present invention expands, and drug effect strengthens, and not only sick for early stage amentia, the amentia disease that disturbance of blood circulation causes also can medication.
The specific embodiment
Below in conjunction with embodiment, the present invention is described further.
Embodiment 1
Raw material is as follows:
After raw material is mixed, be prepared into according to a conventional method capsule.
Embodiment 2
Raw material is as follows:
After raw material is mixed, be prepared into according to a conventional method powder.
Embodiment 3
Raw material is as follows:
After raw material is mixed, be prepared into according to a conventional method pill.
Embodiment 4
Raw material is as follows:
After raw material is mixed, be prepared into according to a conventional method tablet.
Embodiment 5
Raw material is as follows:
After raw material is mixed, be prepared into according to a conventional method capsule.
Embodiment 6
Raw material is as follows:
After raw material is mixed, be prepared into according to a conventional method capsule.
Claims (1)
1. treat a pharmaceutical composition for amentia, it is characterized in that being made by the raw material of following parts by weight:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410391892.2A CN104127432A (en) | 2014-08-08 | 2014-08-08 | Pharmaceutical composition for treating amentia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410391892.2A CN104127432A (en) | 2014-08-08 | 2014-08-08 | Pharmaceutical composition for treating amentia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104127432A true CN104127432A (en) | 2014-11-05 |
Family
ID=51800456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410391892.2A Pending CN104127432A (en) | 2014-08-08 | 2014-08-08 | Pharmaceutical composition for treating amentia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104127432A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1286082A (en) * | 1999-09-01 | 2001-03-07 | 珲春图们江精细化工研究院 | Intelligence-developing oral liquid of amino acids |
-
2014
- 2014-08-08 CN CN201410391892.2A patent/CN104127432A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1286082A (en) * | 1999-09-01 | 2001-03-07 | 珲春图们江精细化工研究院 | Intelligence-developing oral liquid of amino acids |
Non-Patent Citations (3)
| Title |
|---|
| WILLIAM SHANKLE等: "《EFFECT OF DISEASE SEVERITY 》", 《ALZHEIMER’S & DEMENTIA》 * |
| 李岩: "《不同孕期应用L-精氨酸对IUGR鼠影响的研究》", 《中国优秀博硕士学位论文全文数据库（硕士）》 * |
| 欧睿杰: "新药上架", 《当代医学》, no. 6, 30 June 2006 (2006-06-30), pages 74 - 75 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bushby et al. | The multidisciplinary management of Duchenne muscular dystrophy | |
| JP4609875B2 (en) | healthy food | |
| Marshall | Lithium as a nutrient | |
| US8334131B2 (en) | Formulations for promoting stem cell nutrition | |
| JP2003113117A (en) | Anti-depressant medicine, anti-climacteric medicine, senile dementia medicine, alzheimer's dementia medicine | |
| CN105476997B (en) | For to restore the medical conditions associated method and composition of Treatment with Folic Acid thyroid gland | |
| JPS62129219A (en) | Nutrient for nerve of cerebrospinal system | |
| CN109820905A (en) | A kind of pharmaceutical composition and its application for treating insomnia | |
| WO2017107863A1 (en) | Composition for treating motor neuron diseases and use thereof | |
| CN103463624A (en) | Bone joint composite nutrient supplement and preparation method thereof | |
| Inanaga | Marked improvement of neurocognitive impairment after treatment with compounds from Hericium erinaceum: A case study of recurrent depressive disorder | |
| Finkel et al. | FP. 24 RAINBOWFISH: Preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA) | |
| CN101637265A (en) | Health food used for improving sleeping | |
| JP5722797B2 (en) | Multivitamin / mineral mix to combat the effects of environmental stress, improve immunity, improve activity, while addressing vitamin and mineral deficiencies without the negative side effects of high-dose nutritional supplements | |
| CN104127432A (en) | Pharmaceutical composition for treating amentia | |
| CN104138389B (en) | The pharmaceutical composition for the treatment of blood circulation disorder class disease | |
| LU500642B1 (en) | Pharmaceutical compositions for treating mental retardation | |
| Vora et al. | Vinpocetine: Hype, hope and hurdles towards neuroprotection | |
| CN104117022A (en) | Traditional Chinese medicinal preparation for treating schizophrenia | |
| Gaikwad et al. | Modafinil-induced fixed drug eruption | |
| CN106135895A (en) | A kind of supplementary | |
| CN102379907B (en) | Ganoderma lucidum double vitamin methionine preparation and production method thereof | |
| CN101181493A (en) | Medicine for treating epilepsy | |
| López-Botello et al. | Nutritional status in patients with Parkinson's disease at a third-level hospital in Northeastern Mexico | |
| US11839622B1 (en) | Consumable nutraceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Chenxi Inventor after: Li Ping Inventor before: Li Ping |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170515 Address after: 255000, No. 12, building 701, East Garden, Nanjing Road, Zhangdian District, Shandong, Zibo Applicant after: Li Jian Address before: 1608, room 1, research building of bio pharmaceutical industry innovation park, No. 255086, Tai Mo Road, hi tech Zone, Shandong, Zibo Applicant before: ZIBO WEIKEXUN MEDICAL TECHNOLOGY CO., LTD. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141105 |